Photocure

Patent Pending Photocure ASA is a Norwegian pharmaceutical company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology, targeting key dermatology and oncology markets. Photocure's strategy is to build a speciality pharma company by developing and commercialising new and innovative products based on its patented photodynamic technology. Photocure’s strategy in dermatology is to continue the development of the dermatology portfolio, with Visonac and other new dermatology products, and build a commercial platform in the US. Photocure's strategy in cancer is to continue the commercialisation of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy.